Comparative clinical assessment of mometasone furoate-azelastine hydrochloride intranasal spray (Ryaltris AZ®) with fluticasone furoate-azelastine hydrochloride intranasal spray in patients with allergic rhinitis in India


  • Kabikant Samantaray Department of ENT, KIMS Hospital, Bhubaneswar, Odisha, India
  • Rajesh Dhir Department of ENT, Dharam hospital, Chandigarh, Punjab, India
  • Sameer Deshmukh Department of ENT, Deshmukh ENT Hospital, Aurangabad, Maharashtra, India
  • Pankaj Srivastava Department of ENT, Pankaj ENT, Lucknow, Uttar Pradesh, India
  • Sagar Bhimrao Bhagat Department of Global Medical Affairs, Glenmark Pharmaceuticals Limited, Mumbai, Maharashtra, India
  • Saiprasad Patil Department of Global Medical Affairs, Glenmark Pharmaceuticals Limited, Mumbai, Maharashtra, India
  • Hanmant Barkate Department of Global Medical Affairs, Glenmark Pharmaceuticals Limited, Mumbai, Maharashtra, India



Mometasone, Azelastine, Fluticasone furoate, Nasal spray, Allergic rhinitis


Background: Allergic rhinitis is a type of IgE-mediated hypersensitivity reaction. ARIA recommends a combination of intranasal corticosteroid and intranasal antihistamine as first-line treatment for allergic rhinitis in moderate to severe AR. The current study aimed to compare the effectiveness and safety of Mometasone furoate-Azelastine hydrochloride Nasal Spray and Fluticasone furoate-Azelastine hydrochloride Nasal Spray for the treatment of allergic rhinitis in India.

Methods: A multicentric, comparative study was carried out across 30 ENT clinics in India. From September to November 2022, medical records were scrutinised for information such as medical history, symptoms, treatment details, clinical results, and adverse events. The mean change in total nasal and non-nasal symptom scores from baseline to the end of treatment was used to assess effectiveness.

Results: 235 received mometasone furoate-azelastine hydrochloride intranasal spray and 221 received Fluticasone furoate-Azelastine hydrochloride (FF-Az) Intranasal Spray. The mean change from the baseline TNSS score at day 14 in the MF-AZ and FF-Az groups was -6.89 (±3.32) and -6.82 (±3.20) respectively, with no significant difference (p=0.81) between the two. Bitterness and nasal irritation was significantly higher in the FF-Az group. There was no hospitalization, SAE, or treatment discontinuation due to AEs among patients in either group.

Conclusions: The study found that intranasal mometasone-azelastine and fluticasone furoate-azelastine sprays were equally effective in relieving nasal and non-nasal symptoms by days 7 and 14, respectively. However, patients in the fluticasone furoate-azelastine group reported more bitter taste and nasal irritation.


Chennakeshavaraju N, Narayana S, Mohiyuddin ASM. Comparative study of the efficacy and safety of intranasal azelastine hydrochloride and fluticasone furoate in the treatment of allergic rhinitis. J Family Community Med. 2020;27(3):186-91.

Bousquet J, Schünemann HJ, Togias A, Bachert C, Erhola M, Hellings PW, et al; Allergic rhinitis and its impact on asthma working group. next-generation allergic rhinitis and its impact on asthma (ARIA) guidelines for allergic rhinitis based on grading of recommendations assessment, development and evaluation (GRADE) and real-world evidence. J Allergy Clin Immunol. 2020;145(1):70-80.

Aneeza WH, Husain S, Rahman RA, Van Dort D, Abdullah A, Gendeh BS. Efficacy of mometasone furoate and fluticasone furoate on persistent allergic rhinoconjunctivitis. Allergy Rhinol. 2013;4(3):e120-6.

Bousquet J, Anto JM, Bachert C. Allergic rhinitis. Nat Rev Dis Primers. 2020;6:95.

Weiner JM, Abramson MJ, Puy RM. Intranasal corticosteroids versus oral H1 receptor antagonists in allergic rhinitis: systematic review of randomised controlled trials. BMJ. 1998;317:1624-9.

Ellis AK, Zhu Y, Steacy LM, Walker T, Day JH. A four-way, double-blind, randomized, placebo controlled study to determine the efficacy and speed of azelastine nasal spray, versus loratadine, and cetirizine in adult subjects with allergen-induced seasonal allergic rhinitis. Allergy Asthma Clin Immunol. 2013; 9(1):16.

Kim M, Ryu G, Kang SY, Kim MA, Yang SI, Lee IH et al. Work group for rhinitis, the korean academy of asthma, allergy and clinical immunology, intranasal antihistamine and corticosteroid to treat allergic rhinitis: a systematic review and meta-analysis. Allergy. 2022;77(11):3436-40.

Meltzer EO, Shekar T, Teper AA. Mometasone furoate nasal spray for moderate-to-severe nasal congestion in subjects with seasonal allergic rhinitis. Allergy Asthma Proc. 2011;32:159-67.

Bielory L, Chun Y, Bielory BP, Canonica GW. Impact of mometasone furoate nasal spray on individual ocular symptoms of allergic rhinitis: A meta-analysis. Allergy. 2011;66:686-93.

Maspero JF, Walters RD, Wu W. An integrated analysis of the efficacy of fluticasone furoate nasal spray on individual nasal and ocular symptoms of seasonal allergic rhinitis. Allergy Asthma Proc. 2010; 31:483-92.

Karpishchenko SA, Kolesnikova OM. The effectiveness of the combination of azelastine hydrochloride and mometasone furoate for the intranasal application in the patients presenting with seasonal allergic rhinitis. Vestn Otorinolaringol. 2017; 82(5):44-7.

Lange B, Lukat KF, Rettig K, Holtappels G, Bachert C. Efficacy, cost-effectiveness, and tolerability of mometasone furoate, levocabastine, and disodium cromoglycate nasal sprays in the treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 2005; 95(3):272-82.

Horak F. Effectiveness of twice daily azelastine nasal spray in patients with seasonal allergic rhinitis. Ther Clin Risk Manag. 2008;4(5):1009-22.






Original Research Articles